Nisa Leung is a Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages funds with over USD 2.5 billion in assets and investment in over 160 companies. Nisa currently sits on the board of Gan & Lee Pharmaceutical, Zai Lab, Novast Pharmaceuticals, Nurotron Biotechnology, Venus Medtech, Goodwill Infotech, CanSino Biotechnology and Berry Genomics. Nisa oversees Qiming’s investment in CITIC Pharmaceuticals (acquired by Shanghai Pharmaceuticals), OriGene Technologies, Shenogen, Crown Bioscience, Richen, Aeonmed, VR Medical Group, Wuxi Leiming and ACEA Biosciences.Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently China Pharmaceutical Innovation Investment Committee member, convener of Venture Investors Alliance of Hong Kong, advisor of Our Hong Kong Foundation, director of Hong Kong Science and Technology Parks Corporation, council member of HKUST Business School and serves on the Board of Governors of the Hotchkiss School.